Suppr超能文献

地塞米松与曲安奈德注射治疗特发性扳机指的前瞻性随机对照试验

A prospective randomized controlled trial of injection of dexamethasone versus triamcinolone for idiopathic trigger finger.

作者信息

Ring David, Lozano-Calderón Santiago, Shin Robert, Bastian Peter, Mudgal Chaitanya, Jupiter Jesse

机构信息

Harvard Medical School, Boston, MA, USA.

出版信息

J Hand Surg Am. 2008 Apr;33(4):516-22; discussion 523-4. doi: 10.1016/j.jhsa.2008.01.001.

Abstract

PURPOSE

This study was designed to test the null hypothesis that there is no difference in resolution of triggering 3 months after injection with either a soluble (dexamethasone) or insoluble (triamcinolone) corticosteroid for idiopathic trigger finger.

METHODS

Eighty-four patients were enrolled in a prospective randomized controlled trial comparing dexamethasone and triamcinolone injection for idiopathic trigger finger. Sixty-seven patients completed the 6-week follow-up (35 triamcinolone arm, 32 dexamethasone arm), and 72 patients completed the 3-month follow-up (41 triamcinolone arm, 31 dexamethasone arm). Outcome measures included the Disabilities of the Arm, Shoulder, and Hand (DASH) questionnaire, trigger finger grading according to Quinnell, and satisfaction on a visual analog scale. To preserve autonomy, patients were permitted additional injections and operative treatment at any time. Twenty-five patients requested a second injection (10 triamcinolone arm, 15 dexamethasone arm), and 21 elected operative treatment (10 triamcinolone arm, 11 dexamethasone arm) during the study period. The analysis was according to intention to treat principles.

RESULTS

Six weeks after injection, absence of triggering was documented in 22 of 35 patients in the triamcinolone cohort and in 12 of 32 patients in the dexamethasone cohort. The rates 3 months after injection were 27 of 41 in the triamcinolone cohort and 22 of 31 in the dexamethasone cohort. The triamcinolone cohort had significantly better satisfaction and Quinnell grades than did the dexamethasone cohort at the 6-week follow-up but not at the 3-month follow-up. There were no significant differences between Disabilities of the Arm, Shoulder, and Hand scores at the 6-week follow-up and the 3-month follow-up. After the close of the study, there were 8 recurrences among patients with documented absence of triggering in the triamcinolone cohort and 1 in the dexamethasone cohort.

CONCLUSIONS

Although there were no differences 3 months after injection, our data suggest that triamcinolone may have a more rapid but ultimately less durable effect on idiopathic trigger finger than does dexamethasone.

摘要

目的

本研究旨在检验零假设,即对于特发性扳机指,注射可溶性皮质类固醇(地塞米松)或不溶性皮质类固醇(曲安奈德)3个月后扳机症状缓解情况无差异。

方法

84例患者纳入一项前瞻性随机对照试验,比较地塞米松和曲安奈德注射治疗特发性扳机指的效果。67例患者完成了6周随访(曲安奈德组35例,地塞米松组32例),72例患者完成了3个月随访(曲安奈德组41例,地塞米松组31例)。观察指标包括上肢、肩部和手部功能障碍(DASH)问卷、根据奎内尔法进行的扳机指分级以及视觉模拟量表上的满意度。为保持自主性,患者可随时接受额外注射和手术治疗。研究期间,25例患者要求进行第二次注射(曲安奈德组10例,地塞米松组15例),21例患者选择手术治疗(曲安奈德组10例,地塞米松组11例)。分析遵循意向性治疗原则。

结果

注射后6周,曲安奈德组35例患者中有22例无扳机症状,地塞米松组32例患者中有12例无扳机症状。注射后3个月,曲安奈德组41例中有27例,地塞米松组31例中有22例。在6周随访时,曲安奈德组的满意度和奎内尔分级明显优于地塞米松组,但在3个月随访时并非如此。6周随访和3个月随访时,上肢、肩部和手部功能障碍评分无显著差异。研究结束后,曲安奈德组记录为无扳机症状的患者中有8例复发,地塞米松组有1例复发。

结论

尽管注射3个月后无差异,但我们的数据表明,与地塞米松相比,曲安奈德对特发性扳机指的起效可能更快,但最终效果维持时间较短。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验